2024
|
G/S
|
Provision of educational services relating to health; Publication of the results of clinical tria... |
|
G/S
|
Promoting public awareness of blood conditions, diseases, disorders, and treatment; promoting the... |
|
G/S
|
Pharmaceuticals, medical and veterinary preparations and substances; biological and biotechnologi... |
|
G/S
|
blood products; fibrinogen concentrate for human medicine; pharmaceutical products; blood clottin... |
|
Invention
|
Combination therapy using a factor xii inhibitor and a c-1 inhibitor.
Methods and compositions a... |
2023
|
G/S
|
Pharmaceutical preparations; antibodies for medical use. |
|
G/S
|
Pharmaceutical preparations; antibodies for medical use. |
|
G/S
|
Arranging of award ceremonies to recognise achievement; Arranging of conferences; Arranging and c... |
|
G/S
|
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodefici... |
2021
|
Invention
|
Method for treating antibody-mediated rejection.
The invention relates to methods of treating an... |
|
Invention
|
Method for treating antibody-mediated rejection. The invention relates to methods of treating ant... |
|
Invention
|
Method of purifying therapeutic proteins.
The present invention relates generally to a method of... |
2020
|
Invention
|
Pharmaceutical formulations of c1 esterase inhibitor. The present invention relates to pharmaceut... |
|
Invention
|
Process for purifying c1-inh.
The present invention relates to a process for purifying C1-estera... |
|
Invention
|
Process for purifying c1-inh. The present invention relates to a process for purifying C1-esteras... |
2019
|
Invention
|
Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived ... |
|
Invention
|
Proteolytically cleavable fusion proteins with high molar specific activity.
The invention relat... |
|
Invention
|
Methods of administering inhibitory anti-factor xii/xiia monoclonal antibodies. The invention rel... |
|
Invention
|
Therapy using a factor xii inhibitor in a neurotraumatic disorder. The present invention relates ... |
|
Invention
|
Treatment and prevention of remote ischemia-reperfusion injury. The present invention relates to ... |
2018
|
Invention
|
Hydrophobic charge induction chromatographic protein depleted solution. (ii) recovering a solutio... |
|
Invention
|
Method for virus filtration of von willebrand factor.
The present invention relates to a method ... |
|
Invention
|
Method for virus filtration of von willebrand factor. The present invention relates to a method o... |
|
Invention
|
Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings... |
|
Invention
|
A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedin... |
2017
|
Invention
|
Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor... |
|
Invention
|
Pharmaceutical formulations of c1 esterase inhibitor.
The present invention relates to pharmaceu... |
|
Invention
|
Sugar compositions for treating hemophilia a and/or von willebrand disease. The invention relates... |
2016
|
Invention
|
Nucleic acids encoding inhibitory anti-factor xii/xiia monoclonal antibodies. The invention relat... |
|
Invention
|
Modified coagulation factor viia with extended half-life.
The present invention relates to the f... |
|
Invention
|
Factor xii inhibitors for the administration with medical procedures comprising contact with arti... |
2015
|
Invention
|
Improved factor viii preparations suitable for therapeutic use and processes to obtain these.
Th... |
|
Invention
|
Improved factor viii preparations suitable for therapeutic use and processes to obtain these. The... |
|
Invention
|
Therapy using a factor xii inhibitor in a neurotraumatic disorder.
The present invention relates... |
2014
|
Invention
|
Therapeutic agent for amniotic fluid embolism. The present invention relates to a therapeutic age... |
2013
|
Invention
|
Hydrophobic charge induction chromatographic depletion of a protein from a solution. The present ... |